Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

Authors

  • Helge Haarstad From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway
  • Per E. Lønning From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway
  • Stein Gundersen From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway
  • Erik Wist From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway
  • Nils Raabe From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway
  • Stener Kvinnsland From the Department of Oncology, Trondheim University Hospital, Trondheim (H. Haarstad), Department of Oncology, Haukeland University Hospital, Bergen (P.E. Lonning), Department of Oncology, The Norwegian Radium Hospital, Oslo (S. Gundersen, S. Kvinnsland), Department of Oncology, Tromso University Hospital, Tromso (E. Wist), and the Department of Oncology, Ulleva l University Hospital, Oslo (N. Raabe), Norway

DOI:

https://doi.org/10.1080/028418698430584

Abstract

No Abstract Available

Downloads

Download data is not yet available.

Downloads

Published

1998-01-01

How to Cite

Haarstad, H. ., Lønning, P. E. ., Gundersen, S. ., Wist, E. ., Raabe, N. ., & Kvinnsland, S. . (1998). Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment. Acta Oncologica, 37(4), 365–368. https://doi.org/10.1080/028418698430584

Issue

Vol. 37 No. 4 (1998): Acta Oncologica

Section

Articles